Bradley A. McGregor, MD

Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.

Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.

Bradley McGregor, MD, discusses the rationale of the STRIKE trial of tivozanib plus pembrolizumab in RCC.

Mina M. Fam, MD, and Bradley McGregor, MD, discuss the treatment landscape of testicular cancer during Testicular Cancer Awareness Month.

Bradley McGregor, MD, highlights the outcomes of an exposure response analysis assessing the optimal dose of tivozanib in patients with RCC.

Bradley McGregor, MD, discusses the rationale for analyzing efficacy and safety exposure response to tivozanib in patients with renal cell carcinoma.

Bradley McGregor, MD, discusses the clinical implications of the DAD-IO trial in patients with metastatic urothelial carcinoma.

Bradley McGregor, MD, discusses ongoing trials in patients with non-clear cell renal cell carcinoma (RCC).

Bradley McGregor, MD, discusses the focus of future research efforts in renal cell carcinoma.

Bradley McGregor, MD, discusses future research in metastatic castration-resistant prostate cancer.

Bradley McGregor, MD, discusses the evolving treatment landscape of renal cell carcinoma.

In contrast to the wide array of available therapies in the metastatic setting of renal cell carcinoma, in patients with localized disease, the results of trials investigating adjuvant systemic therapy after nephrectomy have so far been underwhelming.